Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fezolinetant

FDA-approved product (tablet, oral), marketed as Veozah.

Registered studies
32
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Fezolinetant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hot flashes

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other gynecologicals
FDA pharmacologic class
Neurokinin 3 Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli44.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis56.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

32registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fezolinetant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fezolinetant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Hormone thERapy Effects on BRAin-HEART Health During the Menopausal Transition

    NCT07732452 · start 2026-11

    Registered record
    Registry ID
    NCT07732452
    Conditions
    Menopause; Perimenopause; Vasomotor Symptoms; Cardiovascular Disease Risk Factor; Menopausal Hormone Therapy; Cardiac Remodeling; Myocardial Fibrosis; Microvascular Dysfunction; Cognitive Function Assessment
    Interventions
    Transdermal estradiol; Standard of care - non hormonal
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-11
    Completion
    2029-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause; Perimenopause; Vasomotor Symptoms; Cardiovascular Disease Risk Factor +5 more
    InterventionTransdermal estradiol; Standard of care - non hormonal
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause

    NCT07829653 · start 2026-10-31

    Registered record
    Registry ID
    NCT07829653
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-10-31
    Completion
    2028-04-30
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant
    PhasePhase 3
    Registry statusNot yet recruiting

  • Fezolinetant and Vascular Health and Brain Health

    NCT07606664 · start 2026-09-25

    Registered record
    Registry ID
    NCT07606664
    Conditions
    Menopause Hot Flashes
    Interventions
    Placebo; Fezolinetant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-09-25
    Completion
    2029-12-30
    Enrolment
    220

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause Hot Flashes
    InterventionPlacebo; Fezolinetant
    PhasePhase 3
    Registry statusNot yet recruiting

  • A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer

    NCT07783282 · start 2026-08-31

    Registered record
    Registry ID
    NCT07783282
    Conditions
    Prostate Cancer
    Interventions
    fezolinetant; enzalutamide; apalutamide; bicalutamide; GnRH agonist/antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-08-31
    Completion
    2027-04-30
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionfezolinetant; enzalutamide; apalutamide; bicalutamide +1 more
    PhasePhase 1
    Registry statusNot yet recruiting

  • A Trial on Fezolinetant for Vasomotor Symptoms in Men Receiving Androgen Deprivation Therapy (ADT)

    NCT07568236 · start 2026-07-01

    Registered record
    Registry ID
    NCT07568236
    Conditions
    Vasomotor Symptoms; Prostate Cancer
    Interventions
    Fezolinetant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2028-03-31
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasomotor Symptoms; Prostate Cancer
    InterventionFezolinetant; Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

    NCT06975111 · start 2026-03-01

    Registered record
    Registry ID
    NCT06975111
    Conditions
    Menopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular
    Interventions
    Metformin; semaglutide; Anti-hypertensives; Lipid Lowering Medication; Life style intervention; Fezolinetant; Hormonal therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2026-03-01
    Completion
    2030-10-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause; Menopause Hot Flashes; Menopause Related Conditions; Cardiovascular
    InterventionMetformin; semaglutide; Anti-hypertensives; Lipid Lowering Medication +3 more
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

    NCT06957691 · start 2026-01-14

    Registered record
    Registry ID
    NCT06957691
    Conditions
    Prostate Cancer; Prostate Cancer (Adenocarcinoma); Prostate Cancer Metastatic Disease; Prostate Cancer Recurrent; Prostate Carcinoma; Prostate Neoplasm; Prostate Adenocarcinoma; Prostate Cancer With Bone Metastasis; Vasomotor Disturbance; Vasomotor Symptoms; Vasomotor Symptoms (VMS); Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men; Vasomotor Symptoms; Hot Flashes; Androgen Deprivation Therapy; Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma; Androgen-deprivation Therapy; Hot Flashes; Hot Flushes; Hot Flushes and/or Sweats
    Interventions
    fezolinetant - reference formulation; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-01-14
    Completion
    2028-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer; Prostate Cancer (Adenocarcinoma); Prostate Cancer Metastatic Disease; Prostate Cancer Recurrent +16 more
    Interventionfezolinetant - reference formulation; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer

    NCT06972875 · start 2025-12-18

    Registered record
    Registry ID
    NCT06972875
    Conditions
    Prostate CA; Androgen Deprivation Therapy
    Interventions
    Fezolinetant
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-12-18
    Completion
    2027-02
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate CA; Androgen Deprivation Therapy
    InterventionFezolinetant
    PhasePhase 2
    Registry statusRecruiting

  • FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

    NCT06917313 · start 2025-12-05

    Registered record
    Registry ID
    NCT06917313
    Conditions
    Breast Cancer Early Stage Breast Cancer (Stage 1-3)
    Interventions
    Fezolinetant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-12-05
    Completion
    2028-03
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer Early Stage Breast Cancer (Stage 1-3)
    InterventionFezolinetant; Placebo
    PhasePhase 2
    Registry statusRecruiting

  • A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice

    NCT07602530 · start 2025-10-23

    Registered record
    Registry ID
    NCT07602530
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2025-10-23
    Completion
    2027-11-30
    Enrolment
    238

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant
    PhaseNot recorded
    Registry statusRecruiting

  • A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause

    NCT06812754 · start 2025-03-10

    Registered record
    Registry ID
    NCT06812754
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2025-03-10
    Completion
    2026-03-05
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

    NCT06617455 · start 2024-10-31

    Registered record
    Registry ID
    NCT06617455
    Conditions
    Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Breast Ductal Carcinoma In Situ; Localized Breast Carcinoma
    Interventions
    Biospecimen Collection; Fezolinetant; Placebo Administration; Quality-of-Life Assessment; Questionnaire Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2024-10-31
    Completion
    2025-11-21
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Breast Ductal Carcinoma In Situ +1 more
    InterventionBiospecimen Collection; Fezolinetant; Placebo Administration; Quality-of-Life Assessment +1 more
    PhasePhase 2
    Registry statusTerminated

  • A Study in Germany to Learn About the Value of Fezolinetant in Treating Hot Flashes and Night Sweats in Women During Menopause

    NCT07455812 · start 2024-10-29

    Registered record
    Registry ID
    NCT07455812
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-10-29
    Completion
    2026-07-16
    Enrolment
    105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy

    NCT06440967 · start 2024-07-31

    Registered record
    Registry ID
    NCT06440967
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant; Placebo; Tamoxifen; Aromatase inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2024-07-31
    Completion
    2028-04-30
    Enrolment
    982

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant; Placebo; Tamoxifen; Aromatase inhibitor
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause

    NCT06206421 · start 2024-02-22

    Registered record
    Registry ID
    NCT06206421
    Conditions
    Hot Flashes
    Interventions
    Fezolinetant; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2024-02-22
    Completion
    2026-03-19
    Enrolment
    277

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHot Flashes
    InterventionFezolinetant; Placebo
    PhasePhase 3
    Registry statusCompleted